This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe
by Zacks Equity Research
Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Moderna (MRNA) Stock Moves 1.89%: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $193.98, marking a +1.89% move from the previous day.
Pharma Stock Roundup: LLY's Donanemab Gets FDA's CRL, MRNA RSV Jab Study Succeeds
by Kinjel Shah
FDA gives CRL to Lilly's (LLY) Alzheimer's candidate, donanemab. Moderna's (MRNA) phase III study on its mRNA-based RSV vaccine candidate in older adults meets primary efficacy endpoints
Novavax (NVAX) Gets Nod for COVID-19 Booster Jab in South Korea
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine gets approval in South Korea as a booster dose in adults 18 years and older.
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
Moderna (MRNA) Soars 3.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Moderna (MRNA) Up on Upbeat Data From Phase III Study on RSV Jab
by Zacks Equity Research
Data from a late-stage study showed that Moderna's (MRNA) RSV vaccine was 83.7% effective at preventing at least two symptoms in adults aged 60 and older.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is First Trust Multi Cap Value AlphaDEX ETF (FAB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FAB
Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More
by Zacks Equity Research
Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.
Moderna (MRNA) Reports 2023 Business View & Pipeline Updates
by Zacks Equity Research
Moderna (MRNA) expects to record a minimum of $5 billion in revenues from COVID vaccine sales in 2023. It also expects to incur around $4.5 billion as R&D expenses in 2023.
Novavax (NVAX) Names John Jacobs as New CEO, Shares Rise
by Zacks Equity Research
Novavax (NVAX) appoints John C. Jacobs as its new president and chief executive officer, effective Jan 23, 2023.
The Zacks Analyst Blog Highlights Thermo Fisher Scientific, Starbucks, Moderna, Canadian Pacific Railway and Micron Technology
by Zacks Equity Research
Thermo Fisher Scientific, Starbucks, Moderna, Canadian Pacific Railway and Micron Technology are included in this Analyst Blog.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $183.95, moving +2% from the previous trading session.
Top Stock Reports for Thermo Fisher Scientific, Starbucks & Moderna
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc. (TMO), Starbucks Corporation (SBUX) and Moderna, Inc. (MRNA).
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
CytomX (CTMX) Up 55% on Strategic Partnership With Moderna
by Zacks Equity Research
CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.
Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout
by Zacks Equity Research
Moderna (MRNA) inks an agreement to acquire OriCiro for $85 million. The acquisition is expected to expand and boost Moderna's mRNA manufacturing capabilities.
Are Options Traders Betting on a Big Move in Moderna (MRNA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Novavax (NVAX) Starts A New Study on COVID-Flu Combo Jab
by Zacks Equity Research
Novavax (NVAX) initiates a mid-stage study evaluating its COVID-19-Influenza combination and standalone influenza vaccines in adults aged 50 through 80 years.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $179.62, moving +0.42% from the previous trading session.